产品
编 号：F741155
分子式：C19H16FN7O2
分子量：393.37
分子式：C19H16FN7O2
分子量：393.37
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1282606-48-7
产品详情
生物活性：
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.
体内研究：
SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index.Animal Model:Lewis rats
Dosage:5 mg/kg
Administration:P.o.; 4 hours
Result:Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.
Animal Model:Lewis rats
Dosage:2~10 mg/kg
Administration:P.o.; 4 hours
Result:A dose-responsive reduction of plasma triglycerides desaturation index.
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.
体内研究：
SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index.Animal Model:Lewis rats
Dosage:5 mg/kg
Administration:P.o.; 4 hours
Result:Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.
Animal Model:Lewis rats
Dosage:2~10 mg/kg
Administration:P.o.; 4 hours
Result:A dose-responsive reduction of plasma triglycerides desaturation index.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备